RT Journal Article
SR Electronic
T1 Oxidative Phosphorylation as an Emerging Target in Cancer Therapy
JF Clinical Cancer Research
JO Clin Cancer Res
FD American Association for Cancer Research
SP 2482
OP 2490
DO 10.1158/1078-0432.CCR-17-3070
VO 24
IS 11
A1 Ashton, Thomas M.
A1 McKenna, W. Gillies
A1 Kunz-Schughart, Leoni A.
A1 Higgins, Geoff S.
YR 2018
UL http://clincancerres.aacrjournals.org/content/24/11/2482.abstract
AB Cancer cells have upregulated glycolysis compared with normal cells, which has led many to the assumption that oxidative phosphorylation (OXPHOS) is downregulated in all cancers. However, recent studies have shown that OXPHOS can be also upregulated in certain cancers, including leukemias, lymphomas, pancreatic ductal adenocarcinoma, high OXPHOS subtype melanoma, and endometrial carcinoma, and that this can occur even in the face of active glycolysis. OXPHOS inhibitors could therefore be used to target cancer subtypes in which OXPHOS is upregulated and to alleviate therapeutically adverse tumor hypoxia. Several drugs including metformin, atovaquone, and arsenic trioxide are used clinically for non-oncologic indications, but emerging data demonstrate their potential use as OXPHOS inhibitors. We highlight novel applications of OXPHOS inhibitors with a suitable therapeutic index to target cancer cell metabolism. Clin Cancer Res; 24(11); 2482–90. ©2018 AACR.